Vaccitech Limited
Magdalen Centre
The Oxford Science Park
1 Robert Robinson Avenue
Oxford
OX4 4GA
United Kingdom
Tel: +44-01865-818808
Website: https://www.vaccitech.co.uk/
About Vaccitech Limited
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world.
The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. The management team has decades of experience in the development of vaccine products.
Vaccitech is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications. and is actively developing an internal pipeline of therapeutic candidates.
YEAR FOUNDED:
2016
LEADERSHIP:
Founders: Professor Adrian Hill and Professor Sarah Gilbert
TECHNOLOGY
Please click here for Vaccitech's technology
62 articles with Vaccitech Limited
-
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases
11/21/2022
Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET.
-
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
11/10/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.
-
Vaccitech to Present at Upcoming November 2022 Investors Conferences
11/9/2022
Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Gemma Brown will be presenting at the following investment conferences in November.
-
Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B
11/7/2022
Vaccitech plc today announced an update to the interim analysis of safety and efficacy data from its HBV002 trial (NCT04778904).
-
Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300
11/2/2022
Vaccitech plc announced that the Company will be presenting an update on its Phase 1b/2a study of VTP-300, Vaccitech’s novel immunotherapy for chronic hepatitis B, at the American Association for the Study of Liver Disease - The Liver Meeting®, in Washington, D.C., November 4 – 8, 2022.
-
Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients
10/31/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the dosing of the first patients in HBV003.
-
Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm
10/27/2022
Vaccitech plc announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.”
-
Vaccitech to Present at Upcoming October 2022 Investor & Scientific Conferences
10/3/2022
Vaccitech plc announced that the Company’s Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.
-
Vaccitech Promotes Gemma Brown as Chief Financial Officer
9/20/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO).
-
Vaccitech to Present at Upcoming September 2022 Investors Conferences
9/7/2022
Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.
-
Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
8/9/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company’s recent corporate developments.
-
Vaccitech to Present at the William Blair Biotech Focus Conference 2022
7/7/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12.
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
6/22/2022
Vaccitech plc announced an update to the interim analysis of safety and efficacy data from the HBV002 study, which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor of Hepatology and Experimental Medicine at the University of Oxford.
-
Vaccitech to Present at the Jefferies Healthcare Conference - June 06, 2022
6/6/2022
Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.
-
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
5/20/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022.
-
Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments
5/11/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments.
-
Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®
4/6/2022
Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced that it has been notified of the commencement of royalty payments relating to commercial sales of Vaxzevria®.
-
Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
3/25/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Company’s recent corporate developments.
-
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
3/7/2022
Vaccitech plc today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.